Jeff Jacobovitz Quoted in Chemistry World Article on Illumina Merger

Jeff Jacobovitz, AGG trial attorney and chair of the firm’s Antitrust group, was quoted in a Chemistry World article discussing gene sequencing company Illumina’s merger with cancer detection firm Grail. Despite objections from EU and U.S. competition authorities, Illumina proceeded with the merger before receiving approval. Specifically, in the U.S., the Federal Trade Commission (“FTC”) sought to reverse the acquisition on the basis that it would harm innovation and increase prices.

As a former FTC attorney, Jeff shared his insights into the situation.

“In the U.S., the FTC would generally seek an injunction in federal to stop the merger,” said Jeff. “It’s a fairly unusual scenario here.”

To read the full article, please click here.